LENZ Therapeutics, Inc. (LENZ)
3.20
-0.30
(-8.57%)
USD |
NASDAQ |
Nov 18, 16:00
3.21
+0.01
(+0.31%)
After-Hours: 20:00
LENZ Therapeutics Shareholders Equity (Quarterly) : 192.00M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 192.00M |
| June 30, 2026 | 219.26M |
| March 31, 2026 | 246.49M |
| December 31, 2025 | 284.34M |
| September 30, 2025 | 193.93M |
| June 30, 2025 | 206.36M |
| March 31, 2025 | 192.01M |
| December 31, 2024 | 204.08M |
| September 30, 2024 | 215.28M |
| June 30, 2024 | 192.92M |
| March 31, 2024 | 198.17M |
| December 31, 2023 | 50.68M |
| Date | Value |
|---|---|
| September 30, 2023 | 204.02M |
| June 30, 2023 | 224.15M |
| March 31, 2023 | 276.22M |
| December 31, 2022 | 296.29M |
| September 30, 2022 | 316.45M |
| June 30, 2022 | 338.46M |
| March 31, 2022 | 361.30M |
| December 31, 2021 | 389.84M |
| September 30, 2021 | 400.13M |
| June 30, 2021 | 379.18M |
| March 31, 2021 | 176.46M |
| December 31, 2020 | -9.80M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| EyePoint, Inc. | 108.51M |
| Ligand Pharmaceuticals, Inc. | 961.76M |
| Bristol Myers Squibb Co. | 23.40B |
| Context Therapeutics, Inc. | 31.01M |
| Neumora Therapeutics, Inc. | 18.55M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 209.75M |
| Total Liabilities (Quarterly) | 17.75M |
| Debt to Equity Ratio | 0.0024 |
| Current Ratio | 11.66 |
| Net Debt Paydown Yield | 0.10% |